Actuate Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, focusing on oncology. It faces competition from major pharmaceutical and biotechnology firms, academic institutions, government agencies, and public and private research organizations. Its leading clinical asset, Elraglusib Injection ("elraglusib"), is in a Phase 2 clinical trial as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Current standard first-line treatments for mPDAC include GnP, FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), and NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin), which offer modest overall survival benefits. The company is developing elraglusib in combination with GnP. Competitors target pathways such as KRAS, which intersect with GSK-3 pathways, indicating potential for combination therapies with elraglusib. The company recognizes competitors conducting clinical trials or marketing in anticipated regions, as well as other companies, including smaller or early-stage firms and academic and research institutions, as significant competitors.
September 22, 2025
In the ever-evolving landscape of oncology therapeutics, Actuate Therapeutics, Inc. (NASDAQ: ACTU) stands at the forefront, committed to addressing the formidable challenges posed by high-impact, difficult-to-treat cancers. On September 22, 2025, the biopharmaceutical company announced significant regulatory updates surrounding its investigational therapy, elraglusib, focused on the densely populated sphere of pancreatic cancer. As regulatory milestones approach with the FDA and European Medicines Agency (EMA), the latest data highlight a potential paradigm shift in treating metastatic pancreatic cancer.Actuate’s recent achievements were underlined by a remarkable $17.25 million public offering, an investm...
September 16, 2024
Actuate Therapeutics Unveils New Insights into Combating One of the Most Aggressive Cancers At the AACR Special Conference on Advances in Pancreatic Cancer Research, Actuate Therapeutics, Inc. revealed preliminary findings from a Phase 2 trial exploring the use of elraglusib and losartan in conjunction with the FOLFIRINOX regimen for patients with untreated metastatic pancreatic adenocarcinoma. The trial aims to identify safe and effective treatment options for this challenging malignancy with high morbidity and mortality rates. Pancreatic cancer poses one of the most significant challenges in modern oncology, given its late-stage diagnosis and limited treatment efficacy. With an overall 5-year survival...
Sources:
Actuate Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Actuate Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
